Mainz Biomed (NASDAQ:MYNZ – Get Free Report) and Mercury Systems (NASDAQ:MRCY – Get Free Report) are both industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
96.0% of Mercury Systems shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 1.0% of Mercury Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Mainz Biomed and Mercury Systems, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
| Mercury Systems | 2 | 3 | 7 | 1 | 2.54 |
Mercury Systems has a consensus target price of $108.10, suggesting a potential upside of 38.36%. Given Mercury Systems’ stronger consensus rating and higher possible upside, analysts plainly believe Mercury Systems is more favorable than Mainz Biomed.
Profitability
This table compares Mainz Biomed and Mercury Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mainz Biomed | N/A | N/A | N/A |
| Mercury Systems | -0.40% | 2.52% | 1.58% |
Earnings & Valuation
This table compares Mainz Biomed and Mercury Systems”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mainz Biomed | $659,935.00 | 8.69 | -$21.65 million | ($65.60) | -0.01 |
| Mercury Systems | $983.62 million | 4.84 | -$29.67 million | ($0.08) | -976.62 |
Mainz Biomed has higher earnings, but lower revenue than Mercury Systems. Mercury Systems is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Mercury Systems has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Summary
Mercury Systems beats Mainz Biomed on 10 of the 15 factors compared between the two stocks.
About Mainz Biomed
Mainz Biomed is a molecular diagnostics company focused on developing tests for the early detection of cancer. The company is headquartered in Mainz, Germany, and serves markets in Europe and other regions. Its lead product, ColoAlert, is a noninvasive, stool-based screening test designed to detect colorectal cancer and precancerous lesions. The test uses molecular analysis alongside a fecal immunochemical test (FIT). Mainz Biomed is also developing PancAlert, a diagnostic test intended to support the early detection of pancreatic cancer.
About Mercury Systems
Mercury Systems, Inc. develops and supplies secure processing systems and subsystems for the aerospace and defense industries. Its products include embedded computing, signal processing, radio-frequency and microwave components, and other technologies used to process and manage critical data. The company’s technologies support applications such as radar, electronic warfare, communications, avionics, and command-and-control systems. Mercury works with defense contractors and government customers, providing components and systems designed for use in demanding environments.
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
